Swanson G P, Riggs M W, Herman M
The Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Prostate Cancer Prostatic Dis. 2008;11(2):198-202. doi: 10.1038/sj.pcan.4500983. Epub 2007 May 22.
Although the number of men with lymph node-positive prostate cancer has declined, it is still significant and the challenge remains on how best to treat these patients. Only long-term follow-up can give a true indication of the outcome in prostate cancer. We evaluated our experience in treating lymph node-positive prostate cancer with a median follow-up of 10.2 years. The overall 5-year survival was 78% and the 10-year survival was 56%. Length of tumor control depends on the type of treatment given. Adding androgen ablation improves the duration of control dramatically, although optimal timing is still uncertain.
尽管淋巴结阳性前列腺癌男性患者数量有所下降，但仍相当可观，如何最佳治疗这些患者仍是一大挑战。只有长期随访才能真正显示前列腺癌的治疗结果。我们评估了治疗淋巴结阳性前列腺癌的经验，中位随访时间为10.2年。总体5年生存率为78%，10年生存率为56%。肿瘤控制时间取决于所采用的治疗类型。添加雄激素剥夺疗法可显著延长控制时间，尽管最佳时机仍不确定。
